{"id":8112,"date":"2021-07-27T09:27:28","date_gmt":"2021-07-27T09:27:28","guid":{"rendered":"https:\/\/www.dlongwood.com\/endopredict-2\/"},"modified":"2025-05-15T10:37:53","modified_gmt":"2025-05-15T10:37:53","slug":"endopredict","status":"publish","type":"productos","link":"https:\/\/www.dlongwood.com\/en\/product-catalog\/endopredict\/","title":{"rendered":"EndoPredict\u00ae"},"content":{"rendered":"\n<p>EndoPredict is a prognostic and predictive in vitro molecular test for patients with ER+\/HER2- (estrogen receptor positive, human epidermal growth factor receptor 2 negative) primary breast cancer.<\/p>\n\n\n\n<p>This second generation test combines a molecular score, obtained from the analysis of the expression of 12 genes (8 genes relevant to the course of the disease, 3 normalization genes and a control gene), with tumour size and nodal status (negative: N0, or positive: N+), resulting in the &#8220;EPclin Risk Score&#8221;. This score allows the establishment of a low-risk group or a high-risk group for recurrence.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full\"><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-10.png\" target=\"_blank\" rel=\"noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-10.png\" alt=\"\" class=\"wp-image-9131\" title=\"\"><\/a><\/figure><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>By combining the molecular score with clinical parameters (tumour size and nodal status), a prognostic accuracy superior to that of first generation tests is achieved, and it is possible to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-11.png\" target=\"_blank\" rel=\"noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-11.png\" alt=\"\" class=\"wp-image-9133\" title=\"\"><\/a><\/figure><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In this way, EndoPredict answers 3 important clinical questions:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Can chemotherapy be avoided? &#8211; 10-year risk<\/strong><\/li><\/ul>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full\"><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-7.png\" target=\"_blank\" rel=\"noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-7.png\" alt=\"\" class=\"wp-image-9125\" title=\"\"><\/a><figcaption>REFERENCES: 1. Filipits M. et al.: Clin. Cancer Res. 2011, 2. Martin M. et al.: BCR 2014, 3. Buus et al.: J Natl Cancer Inst. 2016, 4. Sestak I. et al.: JAMA Oncol. 2018<\/figcaption><\/figure><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>What is the absolute benefit from chemotherapy at 10 years?<\/strong><\/li><\/ul>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full\"><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-8.png\" target=\"_blank\" rel=\"noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-8.png\" alt=\"\" class=\"wp-image-9127\" title=\"\"><\/a><figcaption>REFERENCES: 5. Sestak I. et al.: Breast Cancer Res Treat. 2019<\/figcaption><\/figure><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Can endocrine therapy be stopped after 5 years? &#8211; Risk after 5 years and up to 15 years<\/strong><\/li><\/ul>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full\"><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-9.png\" target=\"_blank\" rel=\"noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/image-9.png\" alt=\"\" class=\"wp-image-9129\" title=\"\"><\/a><figcaption>REFERENCES: 6. Filipits M. et al.: Clin Cancer Res. 2019<\/figcaption><\/figure><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>EndoPredict is recommended by international guidelines such as ASCO, ESMO, St. Gallen, EGMT, AJCC, AGO or NCCN, is being validated in four large clinical studies (with more than 3,200 patients) and used to guide treatment selection in more than 30,000 patients worldwide.<\/p>\n\n\n\n<p><strong>Key features:<\/strong><\/p>\n\n\n\n<p>\u2022 It is the only test that provides answers to these three questions: Can chemotherapy be avoided? What is the absolute benefit of chemotherapy? Can endocrine therapy be stopped after 5 years?<br>\u2022 It is the test that provides the largest group of &#8220;true&#8221; low-risk patients<br>\u2022 Second generation test, achieving superior prognostic accuracy<br>\u2022 Unique gene selection for accurate short- and long-term risk assessment<br>\u2022 Consistent study cohorts and constant cut-off point<br>\u2022 Clear low and high risk categories<br>\u2022 Fast results: within 2 days by local testing<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-gallery aligncenter columns-3 is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\"><ul class=\"blocks-gallery-grid\"><li class=\"blocks-gallery-item\"><figure><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-32.jpg\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-32.jpg\" alt=\"\" data-id=\"9149\" data-full-url=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-32.jpg\" data-link=\"https:\/\/dlongwood.com\/?attachment_id=9149\" class=\"wp-image-9149\" title=\"\"><\/a><\/figure><\/li><li class=\"blocks-gallery-item\"><figure><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-33.jpg\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-33.jpg\" alt=\"\" data-id=\"9147\" data-full-url=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-33.jpg\" data-link=\"https:\/\/dlongwood.com\/?attachment_id=9147\" class=\"wp-image-9147\" title=\"\"><\/a><\/figure><\/li><li class=\"blocks-gallery-item\"><figure><a href=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-34.jpg\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-34.jpg\" alt=\"\" data-id=\"9145\" data-full-url=\"https:\/\/dlongwood.com\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-34.jpg\" data-link=\"https:\/\/dlongwood.com\/?attachment_id=9145\" class=\"wp-image-9145\" title=\"\"><\/a><\/figure><\/li><\/ul><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Prognostic and predictive molecular in vitro test to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively, in patients with ER+\/HER2- primary breast cancer.<\/p>\n","protected":false},"featured_media":8110,"template":"","tecnologias":[275],"marcas":[243],"familias":[463,468,347,464],"class_list":["post-8112","productos","type-productos","status-publish","has-post-thumbnail","hentry","tecnologias-rt-pcr-en","marcas-myriad-genetics-en","familias-prognosis","familias-reproductive-system","familias-solid-tumor","familias-tumor-types"],"_links":{"self":[{"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/productos\/8112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/productos"}],"about":[{"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/types\/productos"}],"version-history":[{"count":0,"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/productos\/8112\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/media\/8110"}],"wp:attachment":[{"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/media?parent=8112"}],"wp:term":[{"taxonomy":"tecnologias","embeddable":true,"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/tecnologias?post=8112"},{"taxonomy":"marcas","embeddable":true,"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/marcas?post=8112"},{"taxonomy":"familias","embeddable":true,"href":"https:\/\/www.dlongwood.com\/en\/wp-json\/wp\/v2\/familias?post=8112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}